Novo Nordisk said Thursday that the rampant growth of the U.S.' compounded drug industry was hurting Wegovy sales, and warned ...
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...
1don MSN
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...
Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback